Type 2 Diabetes Progresses Faster in Kids, Study Finds


High blood pressure, other complications seen in adolescence

THURSDAY, May 23 (HealthDay News) -- Type 2 diabetes is more aggressive in children than adults, with signs of serious complications seen just a few years after diagnosis, new research finds.
"Based on the latest results, it seems like type 2 is progressing more rapidly in children," said Dr. Jane Chiang, senior vice president of medical affairs and community information for the American Diabetes Association. "Complications are appearing faster, and it appears to be at a more significant rate than we see in adults."
The results are alarming, Chiang and other experts said. "If these children continue to progress this rapidly, we could see many of the consequences of type 2 diabetes at a much younger age, like kidney disease and heart disease," she said.
The findings are from an ongoing study of treatment options for type 2 diabetes in children and teens. Researchers are using data from the same study group to assess factors related to the disease in youth, such as complications.
People with type 2 diabetes have higher than normal blood sugar levels because their body doesn't make or properly use insulin, a hormone needed to convert food into energy. Being overweight is the most significant risk factor for type 2 diabetes, according to the American Diabetes Association. The number of U.S. children with type 2 disease -- usually seen in adults over 40 -- is sizable and growing, experts say.
The study included nearly 700 children with type 2 diabetes who were between 10 and 17 years old at the outset and had had the disease for eight months on average. Type 2 diabetes is rarely seen in children younger than 10, Chiang said. All the participants had a body-mass index (an estimate of body fat based on a ratio of weight to height) at or above the 85th percentile, which is considered overweight.
The children received diabetes education and were randomized to receive one of three treatments: the drug metformin, metformin plus intensive lifestyle changes or metformin plus rosiglitazone (brand name Avandia).
At the start of the study, about 12 percent of participants had high blood pressure (hypertension). Four years later, about 34 percent had high blood pressure, and the risk was highest for males and those who were heavier, according to the report, which was published online May 23 in a special issue of the journal Diabetes Care.
Initial signs of kidney disease, called microalbuminuria, almost tripled in four years -- from 6.3 percent of the children to almost 17 percent, the study found.
Other highlights:
  • Destruction of beta cells -- the cells that produce insulin -- in children and teens occurred at a rate almost four times higher than in adults.
  • Metformin and rosiglitazone improved insulin sensitivity for the first six months of treatment. There was no change in insulin sensitivity for the patients who took metformin and made lifestyle changes, and there was a decrease in insulin sensitivity for youth on metformin alone. In adults, metformin generally improves insulin sensitivity.
  • Children and teens with higher blood sugar levels had the poorest outcomes on oral medications, and needed to begin using insulin sooner.
  • Over three years, the percentage of youth who needed medication to lower their LDL cholesterol (the bad type of cholesterol) increased from 4.5 percent to 10.7 percent. Lifestyle interventions didn't appear to help lower LDL cholesterol, although they did help lower the levels of triglycerides, another type of blood fat.
  • Eye damage occurred at a rate similar to adults. About five years after diagnosis, 13.7 percent of the youths had nonproliferative retinopathy, a condition that blocks blood vessels in the eyes.
"The rapid progression of hypertension and kidney disease was surprising," said Dr. Jane Lynch, the lead author of the hypertension and kidney disease part of the study.
"We really felt like we were on top of these kids as far as treatments, and they still progressed," said Lynch, a professor of pediatrics in the division of endocrinology and diabetes at the University of Texas Health Science Center at San Antonio.
Graham

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)